Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Atosiban (Tractocile) peptide icon, one bubble per amino acidAtosiban (Tractocile)9 residues (approx.)CYITNCPXGEach bubble = one amino acid. Size = residue mass. Color = chemical class.Uses closest standard amino acids for non-standard residues.

Atosiban (Tractocile)

Initial: ~13 min half-life·Injection

Also known as: Tractocile, RWJ-22164, ORG 5436

Six randomized controlled trials back its ability to delay preterm delivery by at least 48 hours. Atosiban (brand name Tractocile) is an oxytocin receptor antagonist given by IV in a hospital to slow contractions long enough for corticosteroids to reach fetal lungs. The EMA approved it in January 2000; the FDA never did. APOSTEL 8 (Lancet, 2025, n=752) found no improvement in composite neonatal outcomes versus placebo at 30 to 33 weeks (RR 0.90, 95% CI 0.58 to 1.40). Obstetricians in Europe and parts of Asia still reach for it when beta-agonist tocolytics carry too much cardiovascular risk, especially in twin and triplet pregnancies.

What Is Atosiban (Tractocile)?

The APOSTEL 8 trial (Lancet, 2025, n=752) changed the conversation around this drug. The study found no improvement in composite neonatal outcomes compared to placebo at 30 to 33+6 weeks of gestation (RR 0.90, 95% CI 0.58 to 1.40). That result puts a hard question mark on routine use beyond 30 weeks.

Atosiban (Tractocile, CAS 90779-69-4) is a synthetic nonapeptide that competitively blocks both oxytocin and vasopressin V1a receptors on uterine muscle cells. The EMA approved it in January 2000 for acute tocolysis between 24 and 33+6 weeks of gestation.

The mechanism is specific. By blocking Gq/11-coupled signaling at the oxytocin receptor, atosiban prevents the intracellular calcium release that drives myometrial contraction. Contraction frequency drops within 10 minutes of the IV bolus. That speed matters because the entire clinical rationale is to buy a 48-hour window for betamethasone to mature fetal lungs.

Maternal tolerability is its strongest clinical argument. Six RCTs showed less tachycardia, less tremor, and less hypotension compared to beta-agonist tocolytics like ritodrine [1][2]. Placental transfer is minimal, with a fetal-to-maternal plasma ratio of 0.12 [3].

The drug sits in a complicated place right now. Approved, widely used in European labor wards, but 2025 data suggests the delivery delay it reliably achieves may not translate into better outcomes for the baby at later gestational ages. The EMA label has not been updated as of October 2026 (product information last revised March 30, 2022).

How Atosiban (Tractocile) Works

Atosiban works through competitive antagonism at two receptor targets on uterine myometrial cells: the oxytocin receptor (OTR) and the vasopressin V1a receptor.

Blocking the OTR is the primary action. Under normal conditions, oxytocin binds the OTR and activates Gq/11 signaling, which triggers phospholipase C. That enzyme cleaves membrane lipids into IP3 and DAG. IP3 releases calcium from intracellular stores; DAG activates protein kinase C. Both pathways converge on the actin-myosin machinery that makes uterine smooth muscle contract.

Atosiban sits on the OTR and prevents this entire cascade. It also blocks oxytocin-mediated release of prostaglandins PGE2 and PGF2alpha from decidual tissue. Those prostaglandins independently stimulate contractions, so shutting them down adds a second layer of suppression.

The V1a receptor component matters more than it might seem. V1a receptors are upregulated in myometrial tissue during late pregnancy. They drive contractile tone independently of oxytocin signaling. Blocking both receptors gives atosiban broader tocolytic coverage than a pure OTR antagonist would achieve.

At recommended IV doses, steady-state plasma levels reach approximately 442 ng/mL within one hour. The drug clears quickly after infusion stops, with a terminal half-life of about 1.7 hours and clearance of 41.8 L/h.

Atosiban (Tractocile) Benefits

  • Atosiban benefits center on buying time during threatened preterm labor while keeping the mother cardiovascularly stable.
  • Delays delivery by 48 hours or more, confirmed across six randomized controlled trials [1][4][2]. That window allows full corticosteroid dosing for fetal lung maturity.
  • Contraction frequency drops within 10 minutes of IV bolus. Rapid onset means less time in active threatened labor before the drug takes effect.
  • Maternal cardiovascular profile is markedly cleaner than beta-agonist alternatives. No clinically meaningful tachycardia, tremor, or chest pain in head-to-head comparisons with ritodrine.
  • Placental transfer is barely detectable: fetal-to-maternal plasma ratio of 0.12 [3]. Among tocolytics, that fetal exposure level is unusually low.
  • No CYP450 enzyme inhibition. Atosiban does not compete for hepatic metabolism, which removes an entire category of drug interaction risk during peripartum care.
  • UK and European guidelines list it as first-line for tocolysis in multiple gestations where beta-agonists carry raised pulmonary edema and cardiac risk.

Atosiban (Tractocile): Science vs Community Consensus

Science Only
Scientific Evidence
Moderate
Based on 9 key studies·Research only

EMA-approved tocolytic (Tractocile, 2000) that delays delivery ≥48h vs placebo.

Dosing studied: 6.75 mg IV bolus over 1 min → 300 mcg/min infusion × 3h → 100 mcg/min ≤45h; max 330.75 mg/course
Read the evidence (key study, limitations)

APOSTEL 8 (Lancet, 2025, n=752) found NO superiority over placebo in composite neonatal outcomes at 30–33+6 weeks (RR 0.90, 95% CI 0.58–1.40), questioning routine use. Delivery delay benefit confirmed; neonatal benefit remains unproven.

Key Study

APOSTEL 8 (Lancet, 2025, PMID 40049187, n=752); APOSTEL III (Lancet, 2016, PMID 26944026, n=510)

Limitations

APOSTEL 8 (2025): no neonatal outcome benefit vs placebo at 30–33+6 weeks. FDA rejected NDA (2000): no US approval. Off-label IVF/FET use: 2025 RCT (n=1,100, PMID 40036869) showed no significant live birth improvement (49.5% vs 44.7%, p=0.10). All evidence is in hospital setting only: no community pharmacokinetic or efficacy data.

Community Experience
Weak
3.5/5
Based on 0 consumer reports: hospital-only drug

No community use exists.

Community dosing: Not applicable: hospital-administered only
Read the reports (what users report 3, common issues 4)

Atosiban is an IV-only drug administered exclusively in a hospital obstetric unit. There are no consumer protocols, self-administration reports, or Reddit/forum discussions. All "community" context is drawn from clinical literature and patient experience within the hospital setting.

What users report (3)
  • Buys 48-hour window for corticosteroid (betamethasone) administration to mature fetal lungs
  • Superior maternal cardiovascular tolerability vs. beta-agonist tocolytics (no tachycardia, tremor)
  • Minimal placental transfer: fetal/maternal plasma ratio only 0.12
Common issues (4)
  • Not FDA-approved: US patients cannot receive it; US clinicians use nifedipine or indomethacin
  • APOSTEL 8 (2025): no improvement in composite neonatal outcomes vs placebo at 30–33+6 weeks
  • Off-label IVF/FET use: two 2025 RCTs show no significant live birth benefit
  • Elevated pulmonary edema risk in multiple gestations and when combined with other tocolytics
Science-Only Evidence

No community use exists by definition (hospital-only IV drug). Within the scientific literature, APOSTEL 8 (Lancet, 2025) introduces significant internal scientific divergence: EMA approval (2000) was granted on the basis of delivery delay vs placebo, but the 2025 RCT shows no improvement in the neonatal outcomes that are the actual goal of tocolysis. The label has not been updated as of October 2026.

Atosiban (Tractocile) Dosage Guide

RegulatoryEMA-approved Tractocile dosing; not FDA-approved: dose from EU labelSource (opens in a new tab)
LevelDose / InjectionFrequency
Beginner6.75 mgIV bolus, then 3h loading infusion, then up to 45h maintenance (48h max)
Moderate6.75 mgIV bolus, then 3h loading infusion, then up to 45h maintenance (48h max)
Aggressive6.75 mgIV bolus, then 3h loading infusion, then up to 45h maintenance (48h max)
Note:

Atosiban is a hospital-only IV drug. There is no subcutaneous version, no self-injection protocol, no home use. Your obstetric team manages everything.

The three-phase protocol is fixed: 6.75 mg bolus over 1 minute, then 300 mcg/min infusion for 3 hours, then 100 mcg/min for up to 45 hours. Maximum total dose per course is 330.75 mg. Treatment cannot exceed 48 hours.

Two separate vial types exist and they are not interchangeable. The bolus vial is 0.9 mL containing 6.75 mg (7.5 mg/mL concentration). The infusion concentrate vial is 5 mL containing 37.5 mg (7.5 mg/mL). For Phase 2 and 3, dilute each 5 mL concentrate vial into 45 mL of 0.9% sodium chloride, Ringer's lactate, or 5% dextrose. Final concentration: 0.75 mg/mL. Loading rate: 24 mL/hour. Maintenance rate: 8 mL/hour.

If contractions return after stopping, retreatment with the identical protocol is permitted. Up to 3 courses are documented clinically.

One thing most non-specialists miss: after the infusion ends, residual OTR blockade can reduce uterine tone at delivery. Make sure delivery notes flag prior atosiban use so uterotonic agents are standing by.

Cycling

Atosiban is not cycled. It is given as a single acute course of up to 48 hours in a hospital setting for preterm labor management. Re-treatment may be initiated if contractions recur, using the same bolus + infusion protocol.

Calculate your Atosiban (Tractocile) dose
Dosing tiers, timing, and cycle length

Or use the universal Peptide Calculator for any peptide.

Atosiban (Tractocile) Protocols by Goal

beginnerFDA Label≤48 hours per course. Retreatment with identical protocol permitted if contractions recur; up to 3 courses used clinically.
Phase 1: IV Bolus
Wk N/A (acute single episode)
6.75 mg · Single IV injection · Intravenous (slow push over 1 minute)
Phase 2: Loading Infusion
Wk N/A
300 mcg/min · Continuous IV infusion for 3 hours · Intravenous
Phase 3: Maintenance Infusion
Wk N/A
100 mcg/min · Continuous IV infusion for up to 45 hours · Intravenous

Expected: Significant reduction in uterine contractions within 10 minutes. Delivery delay ≥48h confirmed. APOSTEL 8 (2025): no significant improvement in composite neonatal outcomes vs placebo at 30–33+6 weeks (RR 0.90, 95% CI 0.58–1.40).

Monitor: Continuous fetal heart rate monitoring (CTG) and tocometry throughout. Maternal BP and pulse every 15–30 min during loading phase; hourly during maintenance. Hourly respiratory assessment in multiple gestations or when concomitant tocolytics previously used. Signs of chorioamnionitis every 4–6h. Blood glucose at baseline and every 12h in gestational diabetes.

How to Inject Atosiban (Tractocile)

  1. 1
    Confirm gestational age is 24+0 to 33+6 weeks

    Screen for chorioamnionitis (temperature, uterine tenderness, discharge character, WBC). Rule out contraindications including premature rupture of membranes after 30 weeks, fetal distress, placenta previa, and eclampsia.

  2. 2
    Step 2

    Administer the IV bolus: draw up the entire 0.9 mL bolus vial (6.75 mg). Inject slowly over exactly 1 minute into a running IV line. Do not push faster.

  3. 3
    Immediately start the loading infusion

    Dilute 37.5 mg/5 mL concentrate vials into 0.9% NaCl, Ringer's lactate, or 5% dextrose to achieve 0.75 mg/mL. Set infusion pump to 24 mL/hour (300 mcg/min). Run for 3 hours. Total loading dose: 54 mg.

  4. 4
    Step 4

    At the 3-hour mark, reduce to maintenance infusion at 8 mL/hour (100 mcg/min). Continue for up to 45 hours. Maximum maintenance dose: 270 mg.

  5. 5
    Step 5

    Monitor continuously: fetal heart rate by CTG, uterine contraction frequency by tocometry, maternal BP and pulse every 15 to 30 minutes during loading then hourly during maintenance. Respiratory assessment hourly; increase to continuous in multiple gestations.

  6. 6
    Step 6

    Stop infusion at 48 hours maximum, or sooner if: fetal distress occurs, chorioamnionitis is confirmed, delivery becomes indicated, or pulmonary symptoms develop.

Total maximum dose per course: 330.75 mg.

Atosiban (Tractocile) Stacking Protocols

Works With

Betamethasone (corticosteroid)

Standard concurrent therapy: the 48-hour tocolytic window exists specifically to allow two doses of betamethasone (12 mg IM × 2, 24h apart) to accelerate fetal lung maturity. This combination is the entire clinical purpose of atosiban.

Betamethasone 12 mg IM, repeat at 24h; begin within first 48h of atosiban infusion

Magnesium sulfate (MgSO4)

Used concurrently for fetal neuroprotection (reduces cerebral palsy risk in preterm neonates <32 weeks). May be co-administered during atosiban infusion per institutional protocol.

Per protocol; typically 4 g IV loading then 1 g/hr maintenance ≤32 weeks

Avoid

Oxytocin

Direct pharmacological antagonism: atosiban is a competitive OT/V1a receptor antagonist. Concurrent oxytocin directly opposes the tocolytic mechanism and negates efficacy.

Do not combine
Carbetocin

Carbetocin is a long-acting oxytocin receptor agonist: directly opposes atosiban's OTR blockade at the same receptor.

Do not combine
Beta-mimetic tocolytics (ritodrine, terbutaline)

Concurrent use significantly increases risk of pulmonary edema, particularly in multiple gestations. All documented post-marketing pulmonary edema cases occurred ~40h into infusion and involved combination tocolytic use.

Do not combine
Calcium channel blockers (nifedipine)

Additive pulmonary edema risk when used with atosiban, especially in multiple pregnancies or nulliparous women. Do not overlap if switching tocolytics.

Estimated Cost

Brand Price
Tractocile (Ferring): ~£120 per 0.9 mL bolus vial (UK NHS hospital procurement, 2024); full 48h course estimate £300–700 depending on number of 5 mL infusion concentrate vials required
Generic / Research
India: ~$50–100 USD/course (Atoziban, Sun Pharma; Tosiban, Zuventus); EU generic forms available within national hospital formulary pricing (not retail)

Pricing updated 2026-04-09

Atosiban (Tractocile) Side Effects

The most serious post-marketing signal is pulmonary edema. It is rare, but every documented case shares the same pattern: onset around 40 hours into infusion, in patients carrying twins or triplets, and nearly always with concomitant tocolytic use. That specificity makes risk prediction straightforward but the consequence severe. Continuous respiratory monitoring (SpO2, respiratory rate, auscultation) is standard during any atosiban infusion lasting beyond 24 hours.

Nausea is the most common maternal side effect at 14% per the EMA SmPC. It typically appears early, within the first hour after bolus injection, and is usually self-limiting.

Common reactions (1 to 10%) include headache, dizziness, tachycardia, hypotension, hot flushes, and vomiting. These are substantially less frequent and less severe than the cardiovascular effects seen with beta-agonist tocolytics. The comparison is part of why European guidelines favor atosiban.

Uncommon effects (0.1 to 1%) include pruritus, rash, uterine hemorrhage, injection site reactions, pyrexia, and hyperglycemia. The hyperglycemia signal deserves attention in patients with gestational diabetes; blood glucose monitoring every 12 hours is recommended in that population.

Rare effects include allergic reactions, insomnia, and uterine atony. The atony concern extends into the postpartum period: residual oxytocin receptor blockade can reduce uterine tone after delivery. Uterotonic agents (oxytocin infusion, ergometrine) should be available at clinical handover.

One safety signal towers above all others in this drug's history. In the important trials, 11 of 15 fetal and infant deaths in the atosiban arm occurred in patients at less than 24 weeks of gestation. This finding is why 24 completed weeks is the absolute gestational age floor for use. Below that threshold, fetal mortality was not comparable to placebo. This contraindication is backed by trial-level mortality data.

Pregnancy status is not a "warning" here because pregnancy is the entire use case. But the gestational window matters enormously: only 24+0 to 33+6 weeks. Outside that range, risk-benefit reverses.

Any patient developing dyspnea, cough, or oxygen desaturation during infusion should have atosiban stopped immediately and receive a chest assessment. Do not wait for a formal pulmonary edema diagnosis before stopping.

Common Issues & Solutions

Verify gestational age is 24+0 to 33+6 weeks before initiating: the <24-week absolute contraindication is evidence-based (11/15 fetal deaths in pivotal trial occurred in the 20–24 week subgroup); the >33+6 week cutoff reflects reversal of risk-benefit at near-term gestations.

If contractions recur after stopping infusion, re-treatment with the identical three-phase protocol is permitted; up to 3 courses are documented clinically, each with the same 330.75 mg/course maximum.

Monitor for pulmonary edema onset at ~40 hours into infusion: highest risk in multiple gestations (twins/triplets) and when concomitant tocolytics were used; all post-marketing pulmonary edema cases occurred at this time point.

Screen for chorioamnionitis before and during treatment (fever >38°C, uterine tenderness, purulent discharge, maternal tachycardia, elevated WBC): tocolysis in the presence of confirmed intrauterine infection is an absolute contraindication.

Post-infusion handover: document atosiban use in delivery notes: OT receptor blockade can persist and reduce postpartum uterine tone; ensure uterotonic agents (oxytocin infusion, ergometrine) are available at handover to manage potential uterine atony.

Ask AI about this page

Ask AI for a second opinion on Atosiban (Tractocile) dosing and side effects

Contraindications

  • Gestational age below 24 weeks or over 33 completed weeks
  • Premature rupture of membranes after 30 weeks gestation
  • Abnormal fetal heart rate indicating fetal distress
  • Antepartum uterine hemorrhage requiring immediate delivery
  • Eclampsia or severe preeclampsia requiring delivery
  • Intrauterine fetal death
  • Suspected intrauterine infection (chorioamnionitis)
  • Placenta previa or abruptio placentae
  • Known hypersensitivity to atosiban or any excipients
  • Hepatic impairment: use with caution, monitor liver function

Drug Interactions

  • Oxytocin and prostaglandins: pharmacological antagonism; concurrent use would negate the tocolytic effect of atosiban
  • Other tocolytic agents: concomitant use may increase risk of pulmonary edema, especially in multiple pregnancies
  • Betamethasone: no clinically relevant interaction identified in studies
  • Labetalol: no clinically relevant interaction identified in studies
  • CYP450-metabolized drugs: atosiban is not a CYP450 substrate and does not inhibit CYP450 enzymes; minimal interaction potential
  • Direct pharmacological antagonism: atosiban is a competitive OT/V1a receptor antagonist. Concurrent oxytocin directly opposes the tocolytic mechanism and negates efficacy.
  • Carbetocin is a long-acting oxytocin receptor agonist: directly opposes atosiban's OTR blockade at the same receptor.

Product Quality

Recommended Monitoring

TestWhenTarget
Fetal heart rate (CTG / electronic fetal monitoring)Continuously throughout infusionNormal FHR 110–160 bpm with adequate variability; no repetitive late or variable decelerations
Uterine contraction frequency and intensity (tocometry)Continuously throughout infusion<4 contractions per 30 minutes; reducing trend from pre-treatment baseline
Maternal pulse and blood pressureEvery 15–30 min during loading phase (Phase 2); hourly during maintenance (Phase 3)BP >90/60 mmHg; HR <100 bpm
Respiratory assessment (SpO₂, respiratory rate, auscultation)Hourly; immediately on any dyspnea, cough, or SpO₂ declineSpO₂ >95%; RR 12–20/min; clear lung fields on auscultation
Chorioamnionitis screen (maternal temperature, uterine tenderness, vaginal discharge character, WBC)At baseline before initiation; every 4–6h during infusionTemperature <38.0°C; no uterine tenderness; no purulent discharge; WBC within gestational norm
Blood glucoseAt baseline; every 12h in patients with gestational diabetes or pre-existing diabetesFasting <5.3 mmol/L (95 mg/dL); 2h post-meal <6.7 mmol/L (120 mg/dL) per GDM targets
Fetal heart rate (CTG / electronic fetal monitoring)

Detect fetal distress requiring immediate delivery despite ongoing tocolysis

Uterine contraction frequency and intensity (tocometry)

Assess tocolytic response; determine if retreatment or additional intervention is needed

Maternal pulse and blood pressure

Detect tachycardia and hypotension (common ADRs, 1–10% per SmPC)

Respiratory assessment (SpO₂, respiratory rate, auscultation)

Early detection of pulmonary edema (post-marketing signal; peak risk ~40h; multiple gestations at highest risk)

Chorioamnionitis screen (maternal temperature, uterine tenderness, vaginal discharge character, WBC)

Chorioamnionitis is an absolute contraindication: tocolysis during intrauterine infection delays delivery while infection worsens, risking maternal sepsis and fetal death

Blood glucose

Hyperglycemia is an uncommon (0.1–1%) ADR per EMA SmPC; clinically significant in GDM patients

Atosiban (Tractocile) Before and After

1-10 minutes

Rapid onset of tocolytic effect after IV bolus; significant reduction in uterine contractions.

1 hour

Steady-state plasma concentration achieved (~442 ng/mL); stable uterine quiescence.

3 hours

Transition from high-dose loading infusion (300 mcg/min) to maintenance infusion (100 mcg/min).

24-48 hours

Critical treatment window: corticosteroids administered to mature fetal lungs; majority of patients remain undelivered.

Post-infusion

Rapid decline in plasma levels after stopping infusion (terminal half-life ~1.7 hours). Uterine activity may return.

What to Expect

1 to 10 minutes: Contraction frequency and intensity drop quickly after the IV bolus hits. OTR occupancy reaches therapeutic levels within minutes. Nausea is the most common early reaction at 14% per the EMA label. Flushing and headache also appear during this window.

1 hour: Plasma concentration settles at steady-state, roughly 442 ng/mL. Uterine quiescence stabilizes. Tachycardia, hypotension, and dizziness can appear at this stage (1 to 10% frequency). Injection site reactions may become noticeable.

3 hours: The infusion rate drops from 300 mcg/min to 100 mcg/min. Uterine suppression holds at the lower rate. This is the window where the first betamethasone dose typically goes in.

24 to 48 hours: The core treatment window. Betamethasone has time to act on fetal lungs. Most patients remain undelivered at 48 hours versus placebo. But APOSTEL 8 (Lancet, 2025, n=752) found no improvement in composite neonatal outcomes versus placebo at 30 to 33+6 weeks. Pulmonary edema risk peaks around the 40-hour mark, particularly in multiple gestations with prior tocolytic use. Hyperglycemia (0.1 to 1%) warrants monitoring in gestational diabetes patients.

Post-infusion: Atosiban clears rapidly once the infusion stops. Terminal half-life is about 1.7 hours; clearance runs at 41.8 L/h. Contractions typically return within hours. Retreatment with the same protocol is an option if they do. Residual OTR blockade can reduce uterine tone at delivery. Uterotonic agents should be staged for the handover.

Detailed Timeline: Science vs Community

1–10 minutes
Science

Significant reduction in contraction frequency and intensity within 10 minutes of IV bolus; rapid OTR occupancy at therapeutic plasma levels.

Community

N/A: hospital setting only

1 hour
Science

Steady-state ~442 ng/mL achieved within 1 hour of infusion start; stable uterine quiescence; maternal cardiovascular parameters should be stabilizing.

Community

N/A

3 hours
Science

Rate reduced from 300 mcg/min to 100 mcg/min; uterine suppression maintained at lower infusion rate. Window for betamethasone first dose.

Community

N/A

24–48 hours
Science

Primary tocolytic goal: 48h for betamethasone to act on fetal lungs and for fetal transfer if required. Majority undelivered at 48h vs placebo. APOSTEL 8 (2025): NO significant improvement in composite neonatal outcomes vs placebo at 30–33+6 weeks.

Community

N/A

Post-infusion
Science

Rapid plasma clearance (terminal t½ ~1.7h; clearance 41.8 L/h). Uterine activity typically returns within hours of stopping. Retreatment may be initiated on recurrence.

Community

N/A

Pharmacokinetics

Half-Life
1.7h
Bioavailability
IV: 100% (administered intravenously)
Tmax
Steady-state reached within 1 hour of infusion start
Data Confidence
high

Source: Terminal half-life (tβ) from EMA SmPC; initial half-life (tα) 0.21 hours. Clearance 41.8 L/h, Vd 18.3 L.

Pharmacokinetics: Active Dose Over Time

t½ = Initial: ~13 min (tα), Terminal: ~1.7 hours (tβ)

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Molecular Profile

Amino Acids
9
Structure
Cyclic
Sequence
CYITNCPXG
HydrophobicPolarPositiveNegativeSpecialHow we generate these icons
Identifiers

Who Should Consider Atosiban (Tractocile)

  • Pregnant women at 24-33 weeks gestation with preterm uterine contractions
  • Patients requiring tocolysis to allow corticosteroid administration for fetal lung maturity
  • Women who cannot tolerate beta-agonist tocolytics due to cardiovascular side effects
  • Patients needing time for maternal transfer to a facility with neonatal intensive care

Related Peptides

What Changed for Atosiban (Tractocile)

No material change since Oct 5, 2026. Checked against Federal Register, openFDA Drugs@FDA, openFDA drug labels, openFDA enforcement reports and PubMed retraction links on Oct 14, 2026. How the change record works

Peptide Schedule Research TeamReviewed Apr 8, 20269 Citations

References

  1. [1]An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double-blind, placebo-controlled trial with tocolytic rescue (opens in a new tab)PubMed (opens in a new tab)Clinical Trial
  2. [2]Treatment of preterm labor with the oxytocin and vasopressin antagonist atosiban (opens in a new tab)PubMed (opens in a new tab)PubMed
  3. [3]The pharmacokinetics of the oxytocin antagonist atosiban in pregnant women with preterm uterine contractions (opens in a new tab)PubMed (opens in a new tab)PubMed
  4. [4]Treatment of preterm labor with the oxytocin antagonist atosiban (opens in a new tab)PubMed (opens in a new tab)PubMed

Related Tools

Storage & Stability

Before Reconstitution
Not applicable: supplied as ready-to-use solution
After Reconstitution
Refrigerate at 2-8°C; after opening, dilute immediately and use within 24 hours
Temperature
2-8°C (36-46°F), protect from light

Frequently Asked Questions

No. Atosiban delays delivery by 48 hours to approximately 7 days in responders; it doesn't resolve the underlying cause of preterm labor. Its purpose is to buy time for corticosteroid administration and neonatal transfer, not to prevent eventual preterm birth. Recurrence of contractions after stopping is common.

The licensed gestational age floor is 24 completed weeks. The pivotal trial showed 11 of 15 fetal/infant deaths in the atosiban arm occurred in the 20–24 week subgroup. At ≥24 weeks, fetal mortality was comparable to placebo. Some specialist centers use it off-label at 23–24 weeks, but this is outside the approved indication and carries documented mortality risk.

Yes, retreatment using the identical three-phase protocol is permitted when contractions recur. Up to 3 courses have been used clinically. The same 330.75 mg dose cap per course applies to each retreatment. Experience beyond 3 courses is limited.

Atosiban is used in multiple gestations, but the risk of pulmonary edema is elevated in twins and triplets, particularly when combined with other tocolytics. Most UK guidelines consider it first-line for multiple gestations because beta-agonists carry even greater cardiovascular risk, but continuous respiratory monitoring is essential.

The FDA rejected the NDA in 2000 based on the US trial showing no neonatal benefit vs. placebo and the mortality signal in the <24-week subgroup. The APOSTEL III trial (The Lancet, 2016, n=510) later confirmed comparable perinatal outcomes to nifedipine at 48 hours. The lack of US approval reflects regulatory risk calculus, not proven inferiority.